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REVIEW
Potential role of the endocannabinoid receptor 
antagonist rimonabant in the management 
of cardiometabolic risk: a narrative review of 
available data 
Abstract: The endocannabinoid system (ECS) is an endogenous physiological system com-
posed of two cannabinoid receptors and several endogenous ligands. The ECS is intimately 
involved in appetite regulation and energy homeostasis, which makes it an intriguing target 
for pharmacological treatment of obesity, diabetes, and the metabolic syndrome. Rimonabant 
is the ﬁ  rst cannabinoid receptor (CB-1) antagonist being studied and utilized to treat obesity 
(it is approved in Europe but is currently under review in the United States). Large random-
ized trials with rimonabant have demonstrated efﬁ  cacy in treatment of overweight and obese 
individuals with weight loss signiﬁ  cantly greater than a reduced calorie diet alone. In addition, 
multiple other cardiometabolic parameters were improved in the treatment groups including 
increased levels of high density lipoprotein cholesterol, reduced triglycerides, reduced waist 
circumference, improved insulin sensitivity, decreased insulin levels, and in diabetic patients 
improvement in glycosylated hemoglobin percentage. There was an increase in the adverse 
effects of depression, anxiety, irritability, and nausea in rimonabant-treated groups. This novel 
medication may become an important therapeutic option in the ﬁ  ght to reduce cardiovascular 
disease worldwide through its unique action on cardiometabolic risk.
Keywords: rimonabant, endocannabinoid, metabolic syndrome, obesity
Introduction
Despite important therapeutic advances, cardiovascular disease (CVD) remains the 
number one cause of death worldwide (World Health Organization 2006a). Traditional 
risk factors for cardiovascular disease include hypertension, dyslipidemia, smoking, 
family history of coronary disease, and aging. Major efforts have been made to identify 
and treat these risk factors with varying degrees of success. Most of the pharmacologi-
cal advances that have been made in reducing cardiovascular risk are designed to treat 
individual traditional risk factors.
Over the past decade, increasing evidence has implicated a number of emerging 
risk factors that also appear to independently identify patients at risk for CVD. The 
ever increasing list of emerging risk factors includes elevated triglycerides (TG), 
small low density lipoprotein cholesterol (LDL-C) particle size, insulin resistance 
and glucose intolerance, proinﬂ  ammatory (as measured by high sensitivity c-reactive 
protein and other assays) states, and prothrombotic states (Grundy et al 2004). Many 
of these risks factors tend to cluster in individual patients compounding their risk 
of developing CVD. These same metabolic abnormalities also appear to predict the 
development of type 2 diabetes mellitus (T2DM). Both the National Cholesterol Edu-
cation Program’s (NCEP) Adult Treatment Panel III and the World Health Organiza-
tion (WHO) have recognized this clustering of risk factors in their deﬁ  nitions of the 
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metabolic syndrome (MetSyn) (Alberti 1998; Expert Panel 
2001). While considerable debate has developed surrounding 
the exact deﬁ  nition and utility of MetSyn, it appears clear 
that these risk factors do indeed cluster in patients who are 
overweight and/or exhibit signiﬁ  cant insulin resistance, and 
that this clustering increases the risk of both CVD (Lakka 
et al 2002) and T2DM (Lorenzo et al 2003), often referred 
to as “cardiometabolic risk.” 
 Despite increased physician and patient awareness, the 
prevalence of obesity, MetSyn, and T2DM are increasing in 
the United States (Ford et al 2004) and worldwide (WHO 
2006b). While lifestyle modiﬁ  cation, including heart-healthy 
eating, caloric restriction, and increased physical exercise, 
remain key to stemming this epidemic of cardiometabolic 
risk, novel pharmacological options that affect weight, 
insulin resistance, and other cardiometabolic risk factors 
simultaneously could have considerable clinical potential. 
Unfortunately, our current guidelines tend to focus on treating 
individual risk factors, and most of our current pharmacologi-
cal interventions do not simultaneously address the multiple 
risk factors associated with increased cardiometabolic risk. 
Concomitant with increased awareness of the importance 
of MetSyn, our understanding of the role the adipocyte plays 
in the development of T2DM and CVD has also evolved. 
Traditionally, adipocytes have been thought of as mere stor-
age depots for energy; however, there is now an increased 
understanding that the abdominal adipocyte is a metabolically 
active endocrine and paracrine organ that plays an important 
role in mediating lipogenesis, glucose homeostasis, and 
inﬂ  ammation, most likely through effects on the synthesis 
of leptin, adiponectin, free fatty acids, tumor necrosis factor 
alfa, and plasminogin activation inhibitor-1 (Kershaw and 
Flier 2004). Pharmacological interventions that could affect 
adipocyte function could have a potentially beneﬁ  cial role 
in the modiﬁ  cation of cardiometabolic risk.
Role of the endocannabinoid system 
in cardiometabolic risk
Over the last 15 years, there has been considerable research 
involving the endocannabinoid system (ECS), an endogenous 
physiological system important in the regulation of feeding 
behavior, lipid metabolism, and energy balance. The system 
is composed of two G-protein cannabinoid receptors (CB-1, 
CB-2) and their associated endogenous ligands (De Petrocel-
lis et al 2004). Anandamide (ADA) and 2-arachidonylgycerol 
(2-AG) are the most studied of the endogenous ligands.
In mammals, CB-1 are found in the central nervous 
system, gastrointestinal organs, and adipose tissue. CB-2 
are found almost exclusively in peripheral immune cells 
and are not thought to be involved in energy homeostasis 
(Howlett et al 2002). 
In the central nervous system, the endocannabinoids 
(ADA and 2-AG) are produced on-demand (not stored in 
vesicles) from phospholipids or triglycerides on the post-
synaptic membrane (Piomelli 2003). Once produced, these 
molecules are immediately released into the synapse where 
they are free to activate the pre-synaptic CB-1 receptor. 
Binding to the pre-synaptic CB-1 receptor then inhibits the 
release of other neurotransmitters stored there (Di et al 2003). 
This process, called retrograde signaling, appears to act as 
a modulatory feedback system controlling neurotransmitter 
release. After interacting with the CB-1 receptor these ligands 
are immediately degraded by the enzymes fatty acid amide 
hydrolase (FAAH) and monoacylglycerol lipase (Cravatt 
et al 1996; Dinh et al 2002).
In the brain, CB-1 are found primarily in the mesolimbic 
areas and the hypothalamus. Compared with lean control 
animals, in the obese mouse model, hypothalamic levels of 
both ADA and 2-AG were found to be higher (Di Marzo 
et al 2001). Interestingly, levels of these ECS ligands were 
signiﬁ  cantly reduced when overweight and normal animals 
were subsequently administered the beneﬁ  cial gut hormone 
leptin. In another experiment, levels of 2-AG and ADA 
were measured in the rat brain during fasting, feeding, and 
after satiation (Kirkham et al 2002). Levels of the endocan-
nabinoids were very high in the mesolimbic area of the 
fasting animals but lower in the feeding animals, suggesting 
this area is involved in motivational behavior to ﬁ  nd and 
consume food.
CB-1 receptors are also found in peripheral tissues includ-
ing adipocytes, pancreas, gut, liver and muscle. Compared 
with lean controls, adipocytes from obese rats exhibited 
a greater than 3-fold upregulation in expression of CB-1, 
demonstrated by increased levels of messenger RNA (Bensaid 
et al 2003). Stimulation of CB-1 in adipose tissue induces li-
poprotein lipase activity while blockade causes up-regulation 
of the protein adiponectin. Adiponectin increases free fatty 
acid oxidation and increased insulin sensitivity in skeletal 
muscle and liver, while decreasing vascular inﬂ  ammation 
(Chandran et al 2003). In skeletal muscle, CB-1 stimulation 
reduces insulin-mediated glucose uptake (Liu et al 2005). 
In the liver, ECS activation leads to increases in de novo 
lipogenesis, a critical component in diet-induced obesity 
(Osei-Hyiaman et al 2005), and in the gastrointestinal tract, 
ADA levels increase during food deprivation suggesting a 
peripheral hunger signal (Gomez et al 2002). Vascular Health and Risk Management 2007:3(2) 183
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Perhaps the most striking examples of the importance of 
the ECS in weight gain and glucose metabolism are demon-
strated in experiments using CB-1 knock-out mice. These 
genetically engineered mice with absent CB-1 represent an 
experimental model of signiﬁ  cantly decreased ECS activa-
tion. CB-1 knockout mice are leaner than wild type mice 
and consume less food (Cota et al 2003). When treated with 
the CB-1 antagonist rimonabant, wild type mice decrease 
food intake to the level of CB-1 knockout mice (Di Marzo 
et al 2001). Ravinet Trillou studied the differences in CB-1 
knockout mice and wild type mice when both were given 
a choice of a very palatable high fat diet or standard diet 
(Ravinet Trillou et al 2004). Wild type mice fed the high fat 
diet exhibited a marked increase in weight compared with 
those fed the standard diet. However, in the CB-1 knockout 
mouse the difference in weight gain between high fat diet and 
standard diet was signiﬁ  cantly attenuated (Table 1). Over the 
course of the study the hyperphagia in wild type mice dimin-
ished but the weight gain over controls continued. The CB-1 
knockout mice also chose the high fat diet, but they did not 
eat excessively and remained lean. Additionally, compared 
with those fed a standard diet, wild type mice fed a high fat 
diet demonstrated a signiﬁ  cantly increased glucose response 
to exogenous insulin injection (increased insulin resistance), 
while once again this effect was markedly attenuated in the 
CB-1 knockout mouse. 
Multiple studies also indicate that the ECS is overactive 
in overweight and obese humans. Engeli et al demonstrated 
that obese women have elevated circulating levels of the 
endocannabinoids and reduced activity of the inactivating 
enzyme FAAH. These levels were not reversed with a 5% 
weight loss (Engeli et al 2005). Sipe et al showed that over-
weight and obese individuals have an approximately two-fold 
increased frequency of an abnormal FAAH gene, resulting 
in decreased activity of this endocannabinoid-inactivating 
enzyme and presumably higher levels of ECS activation 
(Sipe et al 2005). 
Thus, multiple lines of evidence in both human and 
animal models suggest that over-activity of the ECS is 
intimately involved in management of weight, energy, and 
metabolism. As such, interruption of ECS over-activity may 
provide an attractive therapeutic target for management of the 
increased cardiometabolic risk associated with overweight 
and obesity. 
Rimonabant, a selective CB-1 
antagonist
Rimonabant, an orally available selective CB-1 antagonist, 
has shown promise in both animals and humans in the treat-
ment of cardiometabolic risk, especially in patients who are 
overweight, obese, or have T2DM. It represents the ﬁ  rst agent 
affecting the ECS to undergo extensive clinical development. 
Rimonabant has been approved for weight loss in overweight 
and obese persons in Europe, but at the time of this publica-
tion has not been approved in the US.
Pharmacology and pharmacokinetics 
of rimonabant
In healthy human subjects, rimonabant shows linear pharma-
cokinetics in doses up to 20 mg, which is the maximum dose 
used in large-scale clinical trials (Turpault et al 2006). Median 
time to maximal plasma concentration in the obese patient is 
2 hours. The half-life of rimonabant is 6–9 days in non-obese 
subjects; in obese subjects the half-life is approximately 16 
days due to a larger area of distribution. Likewise, the time 
required to reach steady state is also increased in obese sub-
jects (25.5 days) versus the non-obese (12.7 days). Gender 
does not affect pharmacokinetics. In vitro, rimonabant is 
metabolized in part by hepatic CYP3A enzyme pathways, 
leading to the potential for drug interactions with common 
CYP3A inhibitors such as ketokonazole, itraconazole, rito-
navir, and clarithromycin, and inducers such as rifampin, 
phenytoin, phenobarbital, and carbamezapine (Gadde and 
Allison 2006). Further studies are needed to determine the 
clinical signiﬁ  cance of these potential interactions.
Animal data with rimonabant
Ravinet Trillou et al demonstrated that mice with diet induced 
obesity treated with 5 weeks of rimonabant were 20% lighter 
than those receiving placebo (Ravinet Trillou et al 2003). 
In addition, the weight loss in response to a 24-hour fast 
was greater in animals treated with rimonabant, suggesting 
that metabolic effects other than simple reduction of caloric 
intake contributed to the weight loss. The rimonabant 
treated mice also demonstrated a 50% decrease in plasma 
Table 1 Body weight of wild type mice (+/+) and CB1 knockout 
mice (-/-) fed a standard diet (SD) or a free choice of SD and 
high fat diet (SD/HFD) for 12 weeks
Group Body  weight  (g)
SD-/- 31.8  ±  1.2
SD/HFD-/- 34.3  ±  2.4
SD+/+ 41.1  ±  1.6
SD/HFD+/+  48.6 ± 1.6
Adapted from Ravinet Trillou et al (2004). Results reported as mean + standard 
error measure. p < 0.05 for SD-/- vs SD+/+; p < 0.05 for SD/HFD+/+ vs SD+/+.Vascular Health and Risk Management 2007:3(2) 184
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insulin levels, a 53% decrease in leptin levels, a statisti-
cally signiﬁ  cant decrease in non-esteriﬁ  ed fatty acids, and 
statistically signiﬁ  cant improvement in insulin sensitivity. 
When these experiments were repeated in CB-1 knockout 
mice rimonabant had no effect, indicating that the beneﬁ  cial 
effect of rimonabant is mediated entirely through the CB-1 
receptor. Interestingly, CB-1 knockout mice also appear to 
have a greater tendency towards anxiety-like responses and 
anhedonic state (Martin et al 2002).
In an obese rat model, Vickers et al showed that 4 weeks 
of treatment with rimonabant decreased food intake and 
weight. Discontinuation of rimonabant led to increased food 
intake and signiﬁ  cant weight regain (Vickers et al 2003). This 
ﬁ  nding suggests that the effects of rimonabant on weight are 
reversible upon cessation of treatment.
Leptin is a beneﬁ  cial adipose tissue derived neuropep-
tide that appears to be strongly associated with weight and 
metabolism (Kershaw and Flier 2004). Rats with genetically 
deﬁ  cient leptin signaling are obese and are used as a research 
model of obesity. It appears that leptin modulates appetite 
at least in part by reducing levels of endocannabinoids in 
the hypothalamus (Di Marzo et al 2001). As mentioned 
above, Bensaid et al demonstrated that blockade of CB-1 by 
rimonabant increased levels of adiponectin in wild type mice 
and in obese rats with defective leptin signaling (Bensaid et al 
2003). Adiponectin is a protein product of white adipose tissue 
and is beneﬁ  cial in lipid and glucose metabolism. Some of 
the known effects of adiponectin include increasing skeletal 
muscle fatty acid transport and oxidation, improvement of 
hepatic insulin sensitivity, and decreasing vascular inﬂ  am-
mation (Chandran et al 2003). 
Together these animal studies demonstrate that by block-
ing CB-1, administration of rimonabant leads to sustained 
weight loss, decreased free fatty acid levels, and improvement 
in insulin sensitivity that is reversible upon discontinuation of 
the drug. These effects are likely mediated through multiple 
mechanisms including decreased energy intake and changes 
in metabolism related to increases in circulating levels of 
leptin and adiponectin. 
Efﬁ  cacy of rimonabant in clinical trials of 
overweight and type 2 diabetes mellitus
In a 16-week phase IIb trial enrolling obese individuals, aver-
age weight loss was 1.1, 3.5, 3.9, and 4.4 kg for once daily 
doses of placebo, 5 mg, 10 mg, and 20 mg of rimonabant 
respectively (Di Marzo and Matias 2005). In the phase III 
clinical trial program doses of 5 mg and 20 mg daily were 
compared with placebo. Since the 20 mg dose is likely to 
be the most utilized in clinical practice, presentation of the 
results of these trials will focus on that dose. As part of this 
phase III program there have been four major completed, pla-
cebo-controlled, double-blind, randomized controlled trials 
of rimonabant in humans: Rimonabant in Obesity – Europe 
(RIO-EU), Rimonabant in Obesity – Lipids (RIO-Lipids), 
Rimonabant in Obesity – North America (RIO-NA), and 
Rimonabant in Obesity – Diabetes (RIO-DM) (Van Gaal 
et al 2005; Després et al 2005; Pi-Sunyer et al 2006; Scheen 
et al 2006). Participants in all trials were overweight (body 
mass index [BMI] 27 kg/m2) or obese (BMI 30 kg/m2) 
and were randomized to one of three groups, rimonabant 5 mg 
daily, rimonabant 20 mg daily, or placebo and followed for at 
least 1 year. All patients were asked to follow a hypo-calorie 
diet aimed at reducing caloric intake by approximately 600 
kcal/day. In each study, prospective subjects underwent a 
4-week placebo run-in, during which a number of patients 
were excluded; these patients were not included in subsequent 
intention-to-treat (ITT) analysis.
Exclusion criteria common to all four trials included clinically 
signiﬁ  cant cardiovascular, endocrine, pulmonary, neurological, 
dermatological, gastrointestinal, hepatic, hematological, renal, 
and psychiatric diseases (including severe depression). In all 
but the RIO-DM trial diabetic patients were excluded. Com-
mon measured parameters included changes from baseline in 
weight, waist circumference, systolic blood pressure (SBP) and 
diastolic blood pressure (DBP), changes in levels of high den-
sity lipoprotein cholesterol (HDL-C), serum triglycerides (TG), 
fasting glucose, fasting insulin, and total cholesterol to HDL-C 
ratio. In each study, change from baseline in each parameter was 
calculated using ITT, last observation carried forward (LOCF) 
analysis. Detailed differences in methodology and the results of 
each trial are described below.
Rimonabant in obesity – Europe (RIO-EU)
In RIO-EU 1507 obese patients (BMI 30 kg/m2) or over-
weight patients (BMI 27 kg/m2) with either hypertension 
or dyslipidemia were randomized to placebo, 5 mg or 
20 mg of rimonabant daily (Van Gaal et al 2005). Eighty 
per cent of participants were female, 94% were white, and 
the mean age at baseline was 45 years. At baseline, 41% had 
hypertension, 61% had dyslipidemia, and 41% met criteria 
for the metabolic syndrome. The mean baseline weight was 
101 kg. Only 61% of participants completed the trial. In the 
intention to treat (ITT) analysis with the last observation 
carried forward (LOCF) the 5 mg group decreased body 
weight 3.4 kg (p = 0.002 vs placebo) and the 20 mg group 
decreased 6.6 kg (p < 0.001 vs placebo). The proportions of Vascular Health and Risk Management 2007:3(2) 185
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patients who lost at least 5% of their baseline weight after 
1 year were 51%, 33%, and 19% in the 20 mg, 5 mg, and 
placebo groups respectively. Waist circumference decreased 
3.9 cm (p = 0.002 vs placebo) in the 5 mg group and 6.5 cm 
(p < 0.001 vs placebo) in the 20 mg group.
Compared with placebo, 20 mg rimonabant led to statis-
tically signiﬁ  cant increases in HDL-C (+22.3% vs +13.4%; 
p < 0.001) and decreases in total cholesterol to HDL-C ratio, 
triglycerides (–6.8% vs +8.3%; p < 0.0001), fasting glucose, 
fasting insulin, and insulin resistance (measured by the ho-
meostasis model assessment [HOMA]); effects with 5 mg 
rimonabant did not reach statistical signiﬁ  cance compared with 
placebo except in HDL-C (+16.2% vs +13.4%; p = 0.048). 
Based on their statistical analysis, the investigators suggested 
that only approximately 50% of the effect on triglycerides and 
HDL-C could be explained by weight loss, adding support to 
a weight-independent metabolic effect of CB-1 blockade. No 
signiﬁ  cant changes in systolic blood pressure, total cholesterol 
or LDL-C were apparent. In the 20 mg rimonabant group, the 
incidence of MetSyn decreased from a baseline of 42.2% to 
19.6% after 1 year while only changing from 39.9% at baseline 
to 31.4% at 1 year in the placebo group. Table 2 illustrates the 
placebo subtracted change from baseline in the major meta-
bolic variables measured at the completion of the study. 
Rimonabant in obesity – lipids (RIO-Lipids)
In RIO-Lipids 1036 obese or overweight patients (BMI 27–
40 kg/m2) with dyslipidemia (deﬁ  ned by elevated ratio of total 
cholesterol to HDL-C >4.5 in women or >5 in men or elevated 
triglyceride levels >1.69 to 7.90 mmol/L) were randomized to 
placebo, 5 mg or 20 mg of rimonabant daily for 1 year (Després 
et al 2005). Exclusion criteria were similar to the other trials but 
also included patients receiving pharmacological treatment for 
dyslipidemia in the 6 weeks preceding the trial. Approximately 
60% of the participants were female and 62% completed the 
study. Race of the participants was not reported. Baseline mean 
age was 48 years, average weight was approximately 96 kg, 
and average BMI was about 34 kg/m2.
In ITT-LOCF analysis, the 5 mg group decreased weight 
by 3.1 kg (p < 0.001 vs placebo) and the 20 mg group decreased 
weight by 6.9 kg (p < 0.001 vs placebo). The proportion of 
patients who lost at least 10% of their weight after 1 year 
was 33% in the 20 mg group and 7% in the placebo group. 
Waist circumference in the 5 mg group decreased 3.5 cm 
(p = 0.029 vs placebo) and 7.1 cm (p < 0.001 vs placebo) 
in the 20 mg group. HDL-C increased 14.2% (p = 0.025 vs 
placebo) in the 5 mg group and 19.1% (p < 0.001 vs placebo) 
in the 20 mg group. The 20 mg group also showed signiﬁ  -
cant beneﬁ  cial changes in total cholesterol to HDL-C ratio, 
peak size of LDL-C particles, proportion of small LDL-C, 
triglycerides, and fasting insulin levels. Although there were 
no signiﬁ  cant differences between groups, total cholesterol 
increased modestly and LDL-C increased by about 7% in all 
three treatment groups. Systolic and diastolic blood pressure 
demonstrated a modest statistically signiﬁ  cant decrease in the 
20 mg group compared with placebo. Subjects randomized 
to 20 mg rimonabant also demonstrated beneﬁ  cial effects on 
leptin and adiponectin levels that were not seen with placebo. 
In the 20 mg rimonabant group, c-reactive protein decreased 
from 5.0 to 4.1 mg/dL (p = 0.02 vs placebo) compared with 
only a modest decrease from 5.3 to 4.9 mg/dL in the placebo 
group. The 5 mg group did not show statistically signiﬁ  cant 
changes in any of these blood pressure, lipid, or neurohor-
monal parameters. Table 2 illustrates the placebo subtracted 
change from baseline in the major metabolic variables mea-
sured at the completion of the study.
Rimonabant in obesity – North America 
(RIO-NA)
In RIO-NA 3045 obese or overweight subjects were random-
ized to placebo, 5 mg rimonabant or 20 mg rimonabant daily. 
Unique to RIO-NA following the ﬁ  rst year of treatment, pa-
tients who received rimonabant were re-randomized to receive 
the same dose of rimonabant or placebo for a second year; 
subjects initially randomized to placebo remained on placebo 
for the full two years. Females composed 81% of the patients 
and 84% were white. Baseline average weight was approxi-
mately 105 kg and BMI was about 38 kg/m2. Only 52.6% of 
participants completed the ﬁ  rst year of the study. Results in 
this trial were reported as placebo subtracted changes rather 
than the absolute values reported in the other trials. 
In the ITT-LOCF analysis, after one year placebo sub-
tracted weight was reduced 1.3 kg (p < 0.001 vs baseline) 
in the 5 mg group and 4.7 kg (p < 0.001 vs baseline) in the 
20 mg group. In the 20 mg rimonabant group 25% of subjects 
demonstrated at least a 10% weight loss compared with only 
9% in the placebo group. The 20 mg group had statistically 
signiﬁ  cant placebo subtracted improvements in waist cir-
cumference (–3.6 cm; p < 0.001) and triglycerides (–13.2; 
p < 0.001%). Placebo subtracted HDL-C improved 2.3% in 
the 5 mg group (p = 0.01 vs baseline) and 7.2% (p < 0.001 
vs baseline) in the 20 mg group. Total cholesterol to HDL-C 
ratio also improved signiﬁ  cantly in both treatment groups. 
Fasting insulin level decreased (1.7 µU/mL in the 5 mg group 
and 2.8 µU/mL in the 20 mg group) and insulin resistance 
as measured by HOMA improved (Table 2). Prevalence of Vascular Health and Risk Management 2007:3(2) 186
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the MetSyn decreased from a baseline of 34.8% to 21.2% in 
the 20 mg group. Investigators used analysis of covariance 
(ANCOVA) to demonstrate that the effects in HDL-C, TG, 
fasting insulin, and insulin resistance were twice that attribut-
able to the weight loss alone, once again pointing to a weight-
independent effect of CB-1 blockade. Neither treatment 
group showed signiﬁ  cant changes in fasting glucose, SBP, 
or DBP. Table 2 illustrates the placebo subtracted change 
from baseline in the major metabolic variables measured at 
the completion of the ﬁ  rst year of the study. 
During the second year of the study, subjects who contin-
ued to receive 20 mg of rimonabant maintained the weight 
loss achieved during the ﬁ  rst year (placebo subtracted mean 
loss of 7.4 kg) and continued to show signiﬁ  cant beneﬁ  cial 
changes in HDL-C, triglycerides, total cholesterol to HDL-C 
ratio, waist circumference, fasting insulin, and insulin resis-
tance. However, subjects who received rimonabant 20 mg 
the ﬁ  rst year followed by placebo the second year slowly 
regained most of their previously lost weight and waist 
circumference. After completion of year two, subjects who 
received 1 year of rimonabant followed by 1 year of placebo 
had similar weight and metabolic parameters to those who 
received placebo for the full two years. Based on these results, 
it appears that chronic administration of rimonabant, at least 
longer than 1 year, may be necessary in order to maintain the 
beneﬁ  cial clinical effect over the long term. 
Rimonabant in obesity – diabetes (RIO-DM)
Although the results of RIO-DM have been presented at mul-
tiple national meetings and have been widely disseminated, 
the results were not published as a complete manuscript in 
a peer-reviewed journal until fall 2006 (Scheen et al 2006). 
In RIO-DM 1045 overweight or obese patients with T2DM 
were randomized to daily doses of placebo, 5 mg, or 20 mg 
of rimonabant for 1 year in a fashion similar to the above-
mentioned trials. Additional inclusion criteria for RIO-DM 
included monotherapy oral hypoglycemic treatment with 
either metformin or a sulfonylurea for at least 6 months, 
fasting glucose of 5.55–15.04 mmol/L (100–271 mg/dL), 
and hemoglobin A1C (HbA1C) between 6.5% and 10%. 
Exclusion criteria included any clinically signiﬁ  cant micro-
vascular or macravascular diseases related to T2DM, systolic 
BP 160 mmHg, or diastolic BP 95 mmHg, pregnancy, 
lactation, recent change in smoking status, or the use of anti-
obesity drugs in the prior 3 months. In addition, subjects using 
concomitant medications known to affect weight, including 
antidepressants, were excluded. Patient demographics were 
roughly similar across the three treatment groups. Overall, 
88.5% of participants were white and 50.1% were female. 
Average baseline weight was about 98 kg and mean base-
line HgbA1C was 7.3%. The majority of patients were on 
metformin monotherapy at baseline. Sixty-six per cent of 
patients completed the 1-year follow-up. 
In the ITT-LOCF analysis, the placebo group lost 1.4 kg 
body weight compared with a 2.3 kg loss (p = 0.01 vs placebo) 
for the 5 mg treatment group and a 5.3 kg loss (p < 0.0001 vs 
placebo) for the 20 mg group. Waist circumference decreased 
1.9 cm in the placebo group compared with a decreases of 
2.9 cm (p = 0.02 vs placebo) and 5.2 cm (p < 0.0001 vs placebo) 
respectively in the 5 mg and 20 mg groups. Beneﬁ  cial effects 
Table 2 Selected placebo subtracted results from rimonabant in obesity (RIO) trials after 1 year.  Only shown are those results that 
are statistically signﬁ  cant
Measure RIO-EU  RIO-Lipids  RIO-NA  RIO-DM
Weight (kg)  –4.7  –5.4  –4.7  –3.9
Waist circumference (cm)  –4.2  –4.7  –3.6  –3.3
SBP (mmHg)  ns  –1.8  ns  –2.4
DBP  (mmHg)  ns –1.5 ns ns
HDL-C (% change)  8.9  8.1  7.2  8.3
TG (%change)  –15.1  –12.4  –13.2  –16.4
Total C:HDL-C ratio  –0.29  –0.32  –0.28  –0.35
Fasting glucose (mmol/L)  –0.06  ns  ns  –0.97
Fasting insulin (µU/mL)  –2.8 –2.6  –2.8 ns
Peak size LDL-C particle (Å)  nr  1.2  nr  nr
Adiponectin (µg/ml) nr  1.5  nr  nr
Leptin (ng/ml)  nr  –3.8  nr  –3.4
HOMA-IR (%)  –0.7  nr  –0.8  –1.1
CRP (mg/L)  nr  –0.5  nr  –1.4
Data are from ITT-LOCF analysis. Data are placebo subtracted from the 20 mg rimonabant treatment group. 
Abbreviations: ns, not signiﬁ  cant (p > 0.05); nr, not reported; SBP, systolic blood pressure; DBP, diastolic blood pressure; C, cholesterol; HOMA-IR, insulin resistance mea-
sured by homeostasis model assessment; CRP, C-reactive protein.Vascular Health and Risk Management 2007:3(2) 187
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were also seen in fasting glucose, insulin resistance, HDL-
C, total cholesterol to HDL-C ratio, triglycerides, and 
systolic BP. However, after adjusting for weight loss, the 
residual effects on triglycerides and systolic BP were not 
signiﬁ  cant. Like in RIO-Lipids, all three randomized groups 
showed an increase in LDL-C of approximately 7%. Table 2 
illustrates the placebo subtracted change from baseline in 
the major metabolic variables measured at the completion 
of the study. 
Unlike the other studies, RIO-DM also examined change 
in placebo subtracted HbA1C. After one year of therapy, in 
the 20 mg group there was an absolute decrease in HbA1C of 
–0.6% compared with a change of only +0.1% with placebo 
(p < 0.0001). Additionally, 42.9% of the patients receiving 
20 mg of rimonabant achieved a HbA1C of <6.5% compared 
with only 20.8% in the placebo group. According to the 
statistical analysis used by the investigators, the effects of 
rimonabant 20 mg on HbA1C were twice that attributable to 
weight loss alone. A similar side-effect proﬁ  le was seen in 
this trial compared with the other RIO trials and is discussed 
in the following section.
Safety and tolerability of rimonabant 
in the RIO clinical trials
As noted above, in each RIO study a large number of patients 
(34%–47%) did not complete the full year of study drug. 
While concerning, this high drop-out rate is similar to that 
seen in other trials of obesity treatment and there was no 
statistically signiﬁ  cant difference in overall discontinuation 
rates between treatment groups. Although overall discontinu-
ation rates were similar, discontinuations speciﬁ  cally due to 
adverse effects were greater in the rimonabant-treated groups. 
The most common reasons for discontinuation in treatment 
groups included the psychiatric disorders of depression, anxi-
ety, and irritability, followed by nausea. Discontinuation rates 
due to psychiatric complaints and disorders for each of the 
RIO trials are shown in Table 3. Overall, nausea is the most 
common adverse event reported with rimonabant in these 
clinical trials. The incidence of adverse effects diminished 
over time suggesting either a degree of tolerance or that the 
majority of side-effects occurred fairly quickly after initiation 
of treatment. 
All of the RIO trials screened for depression and anxiety 
throughout the studies with the Hospital Anxiety and Depres-
sion Scale (HADS) (Zigmond and Snaith 1983). This scale 
contains 7 items assessing depression and 7 items assessing 
anxiety with each item scored from zero to three. Scores 11 
usually require additional assessment. There were no reported 
differences in groups on this scale; however, exclusion crite-
ria for each study speciﬁ  cally excluded patients with a known 
history of severe depression. Additionally, in three of the 
trials (RIO-Europe, RIO-NA, and RIO-DM) subjects taking 
either antidepressants or medications known to alter weight 
(including anti-depressants) were also excluded. Importantly, 
the number of patients in each group who scored 11 on the 
HADS and the number removed after subsequent psychiatric 
consultation have not been included in the published manu-
scripts (Gadde and Allison 2006). 
Safety was also assessed by examining the effect of treat-
ment on multiple other parameters including QTc intervals on 
electrocardiogram, hematological parameters, liver function, 
kidney function, and blood pressure. No signiﬁ  cant incidence 
of adverse effects was seen in any of these parameters in any 
trials. In RIO-DM there was a higher incidence of hypogly-
cemia in the rimonabant 20 mg group compared with placebo 
(5% vs 2%) and this occurred more frequently in patients on 
concomitant sulfonylurea (but not on metformin) therapy.
Future directions for research 
with rimonabant
The beneﬁ  cial cardiometabolic effects of rimonabant have 
led to interest in further research in multiple areas. Ongoing 
trials include those examining the effects of rimonabant 
on cardiovascular events endpoints (myocardial infarction, 
stroke, or cardiovascular death), progression of atheroma, 
visceral fat accumulation, and prevention of diabetes in 
individuals with impaired glucose tolerance. Of these planned 
clinical trials, perhaps the Strategy to Reduce Atherosclerosis 
Table 3 Discontinuations during RIO trials due to any adverse event and due to psychiatric disorders
  Any adverse event    Psychiatric disorders
  Placebo  Rimonabant 20 mg  Placebo  Rimonabant 20 mg
RIO-EU 9.2%  14.5% 5.2% 7.0%
RIO-Lipid 7.0%  15.0%  2.4%  7.6%
RIO-NA 7.2%  12.8% 2.3% 6.2%
RIO-DM 5.5%  15.0%  0.9% 3.6%Vascular Health and Risk Management 2007:3(2) 188
Bronander and Bloch
Development Involving Administration of Rimonabant: 
the Intravascular Ultrasound Study (STRADIVARIUS) may 
be the most clinically meaningful. This long-term international 
effort will examine the effect of rimonabant therapy on an 
important surrogate endpoint, the progression of coronary ath-
eroma as measured by intravascular ultrasound, using similar 
methodology to what has been done with other proven risk 
reduction strategies. Most of these trials are several years away 
from completion but will answer some important questions 
about the effects of rimonabant in managing cardiometabolic 
risk. These trials should also add important data on safety and 
tolerability in persons with important comorbid conditions. 
Hopefully, future studies will also seek a more diverse 
patient population since the published trials to date have in-
cluded predominantly white patients. It will also be important 
to study the effects of rimonabant in patients with a history of 
mild depression and other psychiatric conditions and in persons 
on pharmacological treatment for depression. The currently 
published trials speciﬁ  cally excluded these conditions yet 
many obese patients either have a diagnosis of or risk factors 
for depression (Herva et al 2006). It will also be important to 
study the effects of rimonabant with concomitant use of other 
weight loss medications such as orlistat and sibutramine as 
well as other lipid-lowering and hypoglycemic agents. Since 
rimonabant works through a unique mechanism, combination 
therapy may offer a cumulative effect on weight loss and other 
cardiometabolic endpoints. 
In addition to effects on cardiometabolic risk, the central 
nervous system effects of rimonabant may be useful in other 
conditions such as tobacco or alcohol dependence. At least one 
large prospective randomized clinical trial investigating the 
use of rimonabant for smoking cessation has been completed. 
The Studies with Rimonabant and Tobacco Use—United 
States (STRATUS-US) was a 10-week trial where chronic 
tobacco users desiring to quit were randomized to either 
placebo, 5 mg rimonabant, or 20 mg rimonabant once daily 
(Anthenelli and Dale 2004). Patients in the 20 mg group 
were more successful at quitting smoking (36%) than the 
placebo group (21%). Nevertheless the US Food and Drug 
Administration (FDA) issued a letter to the manufacturer 
stating that rimonabant will not be considered for smoking 
cessation at this time (Sanoﬁ   Aventis 2006). Future studies 
should continue to look into this indication as well as useful-
ness in other addictive disorders such as alcoholism.
Perspective and conclusion 
Rimonabant has recently received approval for marketing as 
a weight management drug in Europe with the precaution 
that it should not be used in patients with serious uncon-
trolled psychiatric illnesses like major depression or who are 
receiving anti-depressant medication. In the US, the FDA 
issued an “approvable” letter for rimonabant as a weight loss 
agent, but at the time this manuscript was written it has not 
yet received ﬁ  nal approval for marketing in the US (Sanoﬁ   
Aventis 2006).
Assuming that rimonabant will soon be available to prac-
titioners and their patients worldwide, it will be interesting 
to see how this unique therapeutic agent is used clinically. 
Although the absolute magnitude of the effect on weight 
loss is similar to other available pharmacological agents, 
the overall effect on weight is relatively modest, especially 
compared with the effect that can be attained with bariatric 
surgery or medically supervised very low calorie diets in 
motivated individuals. The placebo-corrected reduction in 
weight of about 5 kg seen with rimonabant 20 mg daily in the 
RIO trials, while certainly clinically meaningful, represents 
only a small fraction of the excess weight many overweight 
and obese individuals need to lose in order to signiﬁ  cantly 
improve their health and quality of life. 
Although regulatory agencies have so far offered indica-
tions for rimonabant as a weight management drug only, the 
true potential beneﬁ  t of this novel pharmacological approach 
lies in its ability to positively affect multiple cardiometabolic 
risk factors simultaneously. Since statistical analysis sug-
gests that only approximately 50% of the affect on HDL-C, 
triglycerides, and HgbA1C (in subjects with DM) can be at-
tributed to weight loss alone, presumably rimonabant should 
offer additional beneﬁ  t in reducing cardiometabolic risk over 
and above other similarly effective weight loss strategies. It 
should be noted that in keeping with the design of the RIO 
studies all the results cited in this review use ITT-LOCF 
analysis. Given the high rate of non-completers in these clini-
cal trials, these results underestimate the beneﬁ  ts of those who 
completed 1 year of therapy. At least in RIO-EU, subjects 
who remained on rimonabant for the full year demonstrated 
signiﬁ  cantly more favorable results than those who did not 
complete the study. 
Nonetheless, it should be noted that the changes in 
lipid parameters seen in RIO-Lipids and other studies are 
relatively modest compared with other available therapies 
such as nicotinic acid, ﬁ  brates, and even high dose omega 
3s, and importantly there is no apparent effect on LDL-C, 
the primary target of intervention for patients with dyslip-
idemia according to the US National Cholesterol Education 
Program. As patients on previous lipid lowering agents 
were excluded from RIO-Lipids, it is also unclear whether Vascular Health and Risk Management 2007:3(2) 189
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the effect rimonabant has on lipids will be additive to that 
of other agents, including statins. In patients with diabetes 
the reduction in HgbA1C seen with rimonabant 20 mg 
daily is once again no greater in magnitude than that seen 
with other available oral hypoglycemic agents; however, 
again the effect on other metabolic parameters appears to 
offer a unique beneﬁ  t in reducing cardiometabolic risk. 
Although all the efﬁ  cacy data currently available demon-
strates considerable beneﬁ  t in a number of cardiometabolic 
parameters, determining the true magnitude of reduction in 
cardiometabolic risk will require long-term clinical trials 
(like STRADIVRIOUS) examining the effect on more clini-
cally relevant endpoints than lipid parameters and levels 
of neurohormones. 
Of course, as with all pharmacological interventions, the 
demonstrable beneﬁ  t of rimonabant must be balanced against 
its safety and tolerability proﬁ  le. In the 6600 subjects in 
the RIO studies, rimonabant proved be generally safe and 
well tolerated. However, practitioners must keep in mind that 
this was a highly selected population carefully screened to 
exclude subjects who would be most prone to the psychiatric 
adverse events seen more commonly with rimonabant than 
with placebo. Given the high prevalence of mood and other 
psychiatric disorders among overweight and obese patients, 
pending further trials practitioners will need to be especially 
vigilant in screening for symptoms of depression before ini-
tiation of and during treatment with rimonabant. One ﬁ  nal 
potential limitation of rimonabant as a useful clinical tool 
was also seen in RIO-NA where patients who discontinued 
rimonabant for the second year of the trial had substantial 
weight regain and reversal of previous improvements in lipid 
parameters. As such, it appears that treatment for well past 
1 year may be needed to achieve sustainable reductions in 
cardiometabolic risk. 
In sum, based on its unique mechanism of action, rea-
sonable safety and tolerability proﬁ  le, and the beneﬁ  cial 
improvements in weight, waist circumference, HDL-C, tri-
glycerides and other factors seen in the RIO trials, in patients 
who are not at risk for signiﬁ  cant depression rimonabant 
appears to be a potentially important therapeutic agent in 
helping reduce cardiometabolic risk in overweight and obese 
individuals, especially those with concomitant metabolic syn-
drome or T2DM. Its overall clinical effectiveness in reducing 
the progression of surrogate measures of atherosclerosis 
and the incidence of T2DM and CV events remains to be 
determined, as does its incremental beneﬁ  t when added to 
other risk reduction strategies and its position in our current 
treatment paradigms. 
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